HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed) | RFA DA 22 032

Opportunity Information: Apply for RFA DA 22 032

The NIH grant opportunity titled "HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)" (Funding Opportunity Number RFA-DA-22-032) is a discretionary grant program designed to push early-stage research toward new medication options for opioid-related conditions. It sits under the broader NIH Helping to End Addictions Long-term (HEAL) Initiative, which is aimed at speeding up solutions across the full opioid addiction cycle, not just treating dependence after it is established but also addressing progression to chronic use, withdrawal symptoms, craving, relapse, and overdose. The core idea behind this announcement is to expand the pipeline of potential therapeutics by identifying novel, "druggable" biological targets and creating research probes that can be optimized into future medication candidates.

The scientific focus is on discovery and validation work that helps answer the question: what new mechanisms can be targeted to safely and effectively prevent or treat opioid use disorders (OUD), reduce overdose risk, and address complicated real-world patterns like opioid-polysubstance use. Rather than funding clinical trials, this FOA supports preclinical or translational projects that build a credible case for a target and produce usable chemical or biological tools (often referred to as probes) that can serve as starting points for drug development. In practical terms, the funded research is meant to generate actionable evidence that a target is worth pursuing and to deliver optimizable probe molecules or related research tools that can be refined into potential therapeutics with better safety and efficacy profiles.

Because this is an R21 mechanism, the intent is typically to support exploratory, high-impact projects that can open up new directions, especially where the field needs fresh targets beyond existing medication approaches. The "Clinical Trial Not Allowed" designation is a key boundary: applicants are expected to keep the work on the discovery and early development side rather than testing interventions in human participants as clinical trials. The announcement is structured to help accelerate the front end of the medication development pipeline, bridging the gap between basic mechanistic insights and later-stage preclinical development or eventual clinical testing supported through other mechanisms.

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments that are federally recognized; tribal organizations that are not federally recognized tribal governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal government agencies; regional organizations; U.S. territories or possessions; Indian/Native American Tribal Governments other than federally recognized; and non-domestic (non-U.S.) entities (foreign organizations). This range signals NIH interest in attracting diverse teams and settings, including institutions that serve populations disproportionately affected by opioid harms.

Administrative details from the source information indicate the sponsoring agency is the National Institutes of Health, with CFDA numbers 93.213, 93.279, and 93.846 associated with the opportunity. The posting shows a creation date of July 6, 2021, and an original closing date of October 19, 2021. While the data provided does not specify an award ceiling or the expected number of awards, the program purpose is clear: enable discovery of new therapeutic targets and develop optimizable probes to seed the next generation of medications addressing OUD, overdose, and opioid-polysubstance comorbidities under the HEAL Initiative’s medication development priorities (referenced at https://heal.nih.gov/research/medication-options).

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.213, 93.279, 93.846.
• This funding opportunity was created on 2021-07-06.
• Applicants must submit their applications by 2021-10-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DA 22 032

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: